161 related articles for article (PubMed ID: 2272046)
1. Antiemetic action of 5-HT3 receptor antagonists: review of preclinical and clinical results with ICS 205-930.
Gamse R
Cancer Treat Rev; 1990 Sep; 17(2-3):301-5. PubMed ID: 2272046
[TBL] [Abstract][Full Text] [Related]
2. Antiemetic control: 5-HT3 antagonists: review of clinical results, with particular emphasis on ondansetron.
Kidgell AE; Butcher ME; Brown GW
Cancer Treat Rev; 1990 Sep; 17(2-3):311-7. PubMed ID: 2176933
[No Abstract] [Full Text] [Related]
3. A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.
Sorbe BG; Högberg T; Glimelius B; Schmidt M; Wernstedt L; Hansen O; Sörensen BT; Räisänen I; van Oosterom AT; de Bruijn KM
Cancer; 1994 Jan; 73(2):445-54. PubMed ID: 8293412
[TBL] [Abstract][Full Text] [Related]
4. [Recent improvements in antiemetic therapy].
Roila F; Palladino MA; Ciccarese G; Basurto C
Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
[TBL] [Abstract][Full Text] [Related]
5. A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.
Madej G; Krzakowski M; Pawinski A; Lasota W; Rogowski W; Skoneczna I
Semin Oncol; 1994 Oct; 21(5 Suppl 9):3-6. PubMed ID: 9113119
[TBL] [Abstract][Full Text] [Related]
6. Current issues in the management of nausea and vomiting.
Gralla RJ
Ann Oncol; 1993; 4 Suppl 3():3-7. PubMed ID: 8363996
[TBL] [Abstract][Full Text] [Related]
7. On-demand antiemetic treatment with the serotonine antagonist tropisetron in cisplatin-treated cancer patients.
Havsteen H; Andersen LJ; Kjaer M; Dalmark M
Anticancer Drugs; 1994 Aug; 5(4):410-8. PubMed ID: 7949244
[TBL] [Abstract][Full Text] [Related]
8. Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban).
Morrow GR; Hickok JT; Rosenthal SN
Cancer; 1995 Aug; 76(3):343-57. PubMed ID: 8625113
[TBL] [Abstract][Full Text] [Related]
9. Prospective randomized comparison of tropisetron with and without dexamethasone against high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting.
Malik I; Moid I; Khan Z; Hussain M
Am J Clin Oncol; 1999 Apr; 22(2):126-30. PubMed ID: 10199444
[TBL] [Abstract][Full Text] [Related]
10. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
11. An open, randomized study to compare the efficacy and tolerability of tropisetron with that of a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.
Sorbe B; Hallén C; Frankendal B
Cancer Chemother Pharmacol; 1994; 33(4):298-302. PubMed ID: 8281622
[TBL] [Abstract][Full Text] [Related]
12. [The antiemetic action of tropisetron (Navoban) in the cytostatic treatment of neoplastic diseases].
Buiuc AI; Găleşanu MR
Rev Med Chir Soc Med Nat Iasi; 1996; 100(3-4):160-4. PubMed ID: 9455457
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis.
Chang TC; Hsieh F; Lai CH; Tseng CJ; Cheng HH; Li CL; Michael BJ; Soong YK
Cancer Chemother Pharmacol; 1996; 37(3):279-85. PubMed ID: 8529290
[TBL] [Abstract][Full Text] [Related]
14. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
[TBL] [Abstract][Full Text] [Related]
15. 5-HT3 receptor antagonists, a new approach in emesis: a review of ondansetron, granisetron and tropisetron.
Seynaeve C; Verweij J; de Mulder PH
Anticancer Drugs; 1991 Aug; 2(4):343-55. PubMed ID: 1665723
[TBL] [Abstract][Full Text] [Related]
16. Prevention of emesis by ICS 205-930 in children receiving cytotoxic chemotherapy.
Hachimi-Idrissi S; De Schepper J; Maurus R; Otten J
Eur J Cancer; 1993; 29A(6):854-6. PubMed ID: 8484976
[TBL] [Abstract][Full Text] [Related]
17. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
Mantovani G; Macciò A; Curreli L; Lampis B; Ghiani M; Bianchi A; Contu P
Oncol Rep; 1998; 5(1):273-80. PubMed ID: 9458381
[TBL] [Abstract][Full Text] [Related]
18. Tropisetron in the prevention of chemotherapy-induced nausea and vomiting in patients responding poorly to previous conventional antiemetic therapy.
Bruntsch U; Rüfenacht E; Parker I; Drechsler S; de Bruijn K
Ann Oncol; 1993; 4 Suppl 3():25-9. PubMed ID: 8363995
[TBL] [Abstract][Full Text] [Related]
19. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting.
Simpson K; Spencer CM; McClellan KJ
Drugs; 2000 Jun; 59(6):1297-315. PubMed ID: 10882164
[TBL] [Abstract][Full Text] [Related]
20. Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients.
Dogliotti L; Antonacci RA; Pazè E; Ortega C; Berruti A; Faggiuolo R
Drugs; 1992; 43 Suppl 3():6-10. PubMed ID: 1380432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
